Panacea Biotec
add_icon

Panacea Biotec

347.20
-3.15
(-0.90%)
Market Cap
₹- Cr
PE Ratio
-
Volume
74,720.00
Day High - Low
₹351.70 - ₹343.00
52W High-Low
₹581.90 - ₹281.10
ann
There are new updates from the company12 hours ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
134.92
EBITDA
-
Dividend Yield
- %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
-
Forecast For
Actual

Company News

View All News
Caret
neutral
Devender Gupta has stepped down from his position as Chief Financial Officer of Panacea Biotec. The leadership change affects the pharmaceutical company's senior management structure.
negative
Panacea Biotec reported a consolidated net loss of 139 million rupees for Q2, significantly higher than the 48 million rupees loss in the same period last year, while revenue declined to 1.4 billion rupees from 1.47 billion rupees year-over-year. The company's EBITDA shifted from a gain of 70 million rupees in the prior year quarter to a loss of 178 million rupees, indicating deteriorating operational performance.
neutral
Panacea Biotec Publishes Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025Nov 15, 2025
Panacea Biotec Limited published its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 in Business Standard (English) and Desh Sewak (Punjabi) newspapers on November 15, 2025. The company fulfilled its compliance obligations under SEBI Listing Regulations by notifying stock exchanges BSE and NSE about the newspaper publication of its financial results extract.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
790.15
-
#1 -
-
-
-
-
34.61
699.20
-
#1 -
-
-
-
-
43.29
64.57
-
#1 -
-
-
-
-
21.03
554.80
-
#1 -
-
-
-
-
37.85
28,850.00
-
#1 -
-
-
-
-
39.24
42.05
-
#1 -
-
-
-
-
41.15
54.60
-
#1 -
-
-
-
-
42.72
5,001.00
-
#1 -
-
-
-
-
43.40
414.10
-
#1 -
-
-
-
-
43.97
26.95
-
#1 -
-
-
-
-
41.68
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
123
122
114
485
131
129
171
144
134
184
144
173
136
234
158
1,821
151
143
157
163
163
149
159
150
122
155
170
169
184
150
Expenses
116
179
87
258
104
149
132
150
111
144
127
167
134
226
144
171
191
109
124
135
140
147
151
143
130
140
156
159
168
159
EBITDA
7
-57
27
228
27
-20
39
-6
23
40
17
6
2
8
14
1,650
-40
34
33
29
24
2
8
8
-8
14
14
9
16
-9
Operating Profit %
-17 %
-48 %
21 %
-110 %
17 %
-19 %
21 %
-19 %
16 %
21 %
11 %
1 %
-1 %
3 %
8 %
-21 %
-72 %
-4 %
-8 %
-4 %
-8 %
-2 %
-0 %
-4 %
-12 %
5 %
5 %
-20 %
-1 %
-13 %
Depreciation
14
14
52
13
11
11
11
10
11
11
11
12
11
11
11
11
10
10
10
10
10
9
9
9
9
9
9
8
8
8
Interest
25
29
-14
26
41
42
47
45
45
48
46
47
48
50
52
31
1
1
1
1
1
1
1
1
1
1
1
1
1
2
Profit Before Tax
-33
-99
-11
189
-25
-73
-19
-61
-34
-19
-40
-53
-57
-53
-49
1,608
-51
23
22
18
13
-8
-2
-2
-17
5
4
0
7
-19
Tax
3
-2
5
3
3
2
2
9
0
0
0
2
0
0
0
371
5
8
3
31
2
1
1
-0
-1
0
-0
2
3
-5
Net Profit
-35
-97
-16
186
-28
-75
-21
-70
-34
-19
-40
-54
-57
-53
-49
1,238
-56
16
19
-13
11
-8
-2
-2
-16
5
4
-2
4
-14
EPS in ₹
-5.75
-15.83
-2.60
30.35
-4.62
-12.25
-3.48
-11.38
-5.58
-3.16
-6.54
-8.84
-9.36
-8.65
-8.03
202.03
-9.17
2.56
3.16
-2.03
1.79
-1.35
-0.37
-0.23
-2.59
0.77
0.74
-0.31
0.66
-2.27

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
1,290
Fixed Assets
1,144
1,071
1,001
949
806
657
609
622
600
582
567
Current Assets
526
549
533
560
508
683
511
951
562
486
545
Capital Work in Progress
156
161
30
40
23
24
34
17
42
102
128
Investments
5
4
7
7
5
6
0
5
14
40
3
Other Assets
626
619
761
611
542
703
534
1,115
615
517
592
Total Liabilities
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
1,290
Current Liabilities
706
475
588
691
938
452
449
776
330
309
367
Non Current Liabilities
750
930
846
611
90
743
960
109
101
94
92
Total Equity
475
450
366
306
347
196
-232
874
840
838
831
Reserve & Surplus
449
426
340
293
335
139
-257
849
816
814
807
Share Capital
22
22
6
6
6
6
6
6
6
6
6

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-1
-10
-2
9
-2
26
12
-2
-11
7
35
Investing Activities
-37
17
-26
55
-6
-35
-48
1,283
430
7
65
Operating Activities
37
91
131
118
105
-31
107
-108
-423
4
-27
Financing Activities
-1
-117
-107
-164
-101
91
-47
-1,176
-18
-3
-3

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.46 %
72.87 %
72.49 %
72.48 %
72.48 %
72.48 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.27 %
0.27 %
0.37 %
0.38 %
1.16 %
0.78 %
1.06 %
DIIs
1.27 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.29 %
0.43 %
0.43 %
0.54 %
0.00 %
0.00 %
0.84 %
1.07 %
1.16 %
1.17 %
1.49 %
1.52 %
1.81 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
17.34 %
15.21 %
15.57 %
15.99 %
15.14 %
15.60 %
15.79 %
15.97 %
15.82 %
16.15 %
19.20 %
19.63 %
19.90 %
20.42 %
18.11 %
18.98 %
18.45 %
18.17 %
17.69 %
Others
7.80 %
11.20 %
10.84 %
10.42 %
11.27 %
10.81 %
10.33 %
10.02 %
10.16 %
9.73 %
7.21 %
6.78 %
5.40 %
4.79 %
7.49 %
6.99 %
6.41 %
7.05 %
6.96 %
No of Share Holders
27,228
54,313
52,816
52,465
49,563
49,896
49,078
50,533
48,634
47,815
48,878
47,091
46,242
45,513
39,982
35,446
33,593
34,256
33,593

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Sept 2024 332.95 273.05
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 349.80 349.80
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 303.15 340.50
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 324.90 343.90
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 529.05 521.20
14 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Aug 2025 401.40 430.65
30 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2025 425.30 405.60
14 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2025 431.85 404.10

Announcements

Details Of Shares Dematerialized During November 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 201812 hours ago
Announcement under Regulation 30 (LODR)-Change in Management8 days ago
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)8 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2025
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30 2025Nov 14, 2025
Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30 2025Nov 14, 2025
Intimation Regarding Change In Senior Management Personnel In The CompanyS Material Wholly Owned Subsidiary Viz. Panacea Biotec Pharma Limited (PBPL)Nov 13, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderNov 11, 2025
Details Of Shares Dematerialized During October 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Nov 07, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 06, 2025
Board Meeting Intimation for Approving Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 17, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderOct 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Demat Status Report For The Month Of September 2025Oct 07, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderOct 03, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMOct 01, 2025
Proceedings Of The 41St Annual General Meeting Held On September 30 2025Sep 30, 2025
Disclosure Under Regulation 30 Of SEBI LODR RegulationsSep 27, 2025
Closure of Trading WindowSep 26, 2025
Launch Of IndiaS First 100% Toxin-Free And Safe Nikomom Baby Skin Care Products And Staart Prime Infant Milk Substitute Product By CompanyS Wholly-Owned Subsidiary Panacea Biotec Pharma LimitedSep 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Communication Sent To Physical Shareholders To Furnish PAN And KYC DetailsSep 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Demat Status Report For The Month Of August 2025Sep 08, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 08, 2025
Business Responsibility and Sustainability Reporting (BRSR)Sep 08, 2025
Reg. 34 (1) Annual Report.Sep 08, 2025
Intimation Of 41St Annual General Meeting Of The Company To Be Held On Tuesday September 30 2025 At 11:30 A.M. (IST) Through Video Conferencing (VC) / Other Audio Visual Means (OAVM)Sep 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 16, 2025
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter Ended 30.06.2025Aug 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On August 14 2025Aug 14, 2025
Demat Status Report For The Month Of July 2025Aug 07, 2025
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30 2025Aug 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Intimation Under Regulation 30 And Regulation 31A(8) Of The Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations 2015 - Approval For Reclassification Of Mrs. Sunanda Jain Mr. Sumit Jain And Ms. Radhika Jain FroJul 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 11, 2025
Intimation Of Settlement Of Disputes With Apotex Inc. Canada Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 09, 2025
Details Of Shares Dematerialised During June 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jul 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Details Of Shares Dematerialised During May 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018Jun 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
Intimation Regarding Appointment Of Secretarial AuditorMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Standalone And Consolidated Audited Financial Results Along With Auditors Report For The Quarter And Financial Year Ended March 31 2025May 30, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.05%
1
0.00%
0.05%

Technical Indicators